EMIF creates a network that supports a flow from:

- Data Discovery
- Data Assessment
- Data Reuse
EMIF project overview

- 57 partners from 14 European countries
- €56 million worth of resources
- Three projects in one
- Five year project (2013 – 2017)

**ACADEMIC PARTNERS**

- VUmc
- Erasmus MC
- Kings College London
- ARS Toscana
- University of Glasgow
- UPMC
- Göteborgs Universitet
- University of Cambridge
- University of Lisbon
- University of Antwerp
- University of Leeds
- VIB
- University of Pittsburgh
- Max Planck Cellbiology
- University of Poli
- Konstanz University
- VTT

**SME PARTNERS**

- SYNAPSE
- Concentris
- C Custodix
- Janssen
- GenomEdics

**EFPIA PARTNERS**

- EFPIA

**PATIENT ORGANISATION**

- Alzheimer Europe

---

**EMIF-Metabolic**

Identify predictors of metabolic complications in obesity

**EMIF-AD**

Identify predictors of Alzheimer’s Disease (AD) in the pre-clinical and prodromal phase

**EMIF-Platform**

Develop a framework for evaluating, enhancing and providing access to human health data across Europe, support EMIF-Metabolic and EMIF-AD (the specific topics below) as well as support research using human health data in general.
Data available through consortium

- Large variety in “types” of data
  - Primary care data sets
  - Hospital data
  - Administrative data
  - Regional record-linkage systems
  - Registries and cohorts (broad and disease specific)
  - Biobanks

- Data is available from more than 40 million subjects from seven EU countries, including
  - 25,000 subjects in AD cohorts
  - more than 94,000 subjects in metabolic cohorts
# Catalogue – AD cohorts

![EMIF Catalogue - Google Chrome](https://emif-catalogue.eu/c/adcohort)

### EMIF CATALOGUE / EMIF AD

#### EMIF AD / All

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Name</th>
<th>Institution name</th>
<th>Location</th>
<th>Last update</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADGEN</td>
<td>Kuopio-ADGEN</td>
<td>University of Eastern Finland</td>
<td>Kuopio, Kuopio, Pohjois-Savo, Finland</td>
<td>2015-11-06</td>
</tr>
<tr>
<td>ADNI-1</td>
<td>Alzheimer’s Disease Neuroimaging Initiative</td>
<td>University of California</td>
<td>San Francisco County, California, United States</td>
<td>2015-11-06</td>
</tr>
<tr>
<td>ADNI-2</td>
<td>Alzheimer’s Disease Neuroimaging Initiative</td>
<td>University of California</td>
<td>San Francisco County, California, United States</td>
<td>2015-11-06</td>
</tr>
<tr>
<td>ADNI-GO</td>
<td>Alzheimer’s Disease Neuroimaging Initiative</td>
<td>University of California</td>
<td>San Diego County, California, United States</td>
<td>2015-11-05</td>
</tr>
</tbody>
</table>
Participant selection tool

Summary Graph with attribute selection

Subject Selection

Current Age

APOE Genotype

Summary view

Current Age

Subject Count

50-55
60-65
70-75
80-85

Group by: Current Age

M1  M2  M3  M4  M5  M6  M7  M8  M9

Current Age between 50 and 60

APOE Genotype s2, s3, s4

6
‘Impossible’ sample collections realised

- EMIF 500 samples
  - Focus on CSF biomarkers

- EMIF 1000 samples
  - Focus on amyloid load

- Sample and data access facilitated through data catalogue

- Identification and collection of samples and relevant clinical data in matter of weeks rather than months --
Prevalence amyloid positivity

Jansen et al JAMA 2015
Data from electronic health records

6 Electronic health records from 5 countries
183,428 cases of dementia from 2004-12
Person-years coverage prior to dementia diagnosis – 1,049,947
Person-years after dementia diagnosis – 401,823

IPCI = Integrated Primary Care Information database with around 3MM subjects from the Netherlands
Research collaborations in dementia
Conclusion

- Large scale project with multiple stakeholders and data providers. This would be very hard for one pharma company to set up

- Reuse of existing data is cost (and time) efficient

- Valuable results in AD as a result of collaborations (international and cross-sector)

- EMIF provides a foundation for other projects to build on (e.g. EPAD, DP-UK)
Further Information

- **EMIF general**
  - Bart Vannieuwenhuyse (bvannieu@its.jnj.com)
  - Simon Lovestone (simon.lovestone@kcl.ac.uk)
  - Johan van der Lei (j.vanderlei@erasusmc.nl)

- **EMIF-Platform**
  - Johan van der Lei (j.vanderlei@erasusmc.nl)
  - Nigel Hughes (nhuges@its.jnj.com)

- **EMIF-Metabolic**
  - Ulf Smith (ulf.smith@medic.gu.se)
  - Dawn Waterworth (Dawn.M.Waterworth@gsk.com)

- **EMIF-AD**
  - Pieter Jelle Visser (pj.visser@maastrichtuniversity.nl)
  - Johannes Streffer (jstreffe@its.jnj.com)

www.emif.eu

Register for our newsletter!

EMIF is operating under IMI Grant Agreement n°115372